Nutra Pharma Corp (NPHC) Total Non-Current Liabilities (2010 - 2026)

Nutra Pharma has disclosed Total Non-Current Liabilities across 13 years of filings, most recently posting $21.8 million for Q2 2026.

• In Q2 2026, Total Non-Current Liabilities rose 30.89% year-over-year to $21.8 million; the TTM figure through Jun 2026 stood at $21.8 million (up 30.89% YoY), while the FY2025 annual figure was $17.4 million, up 13.29% from the prior year.
• Total Non-Current Liabilities came in at $21.8 million for Q2 2026 at Nutra Pharma, up from $17.8 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $21.8 million in Q2 2026 to a low of $14.2 million in Q3 2023.
• Average Total Non-Current Liabilities over 4 years is $16.4 million, with a median of $16.0 million recorded in 2024.
• The largest YoY upside for Total Non-Current Liabilities was 30.89% in 2026 against a maximum downside of 5.26% in 2026.
• Over 4 years, Total Non-Current Liabilities stood at $14.4 million in 2023, then grew by 6.83% to $15.4 million in 2024, then gained by 13.29% to $17.4 million in 2025, then advanced by 25.2% to $21.8 million in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $21.8 million in Q2 2026, $17.8 million in Q1 2026, and $17.4 million in Q4 2025.